STE Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 12.66% compared to Steris PLC's net margin of 12.41%. Steris PLC's return on equity of 7.27% beat Boston Scientific's return on equity of 8.96%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 12.2%. On the other hand Boston Scientific has an analysts' consensus of $115.37 which suggests that it could grow by 19.22%. Given that Boston Scientific has higher upside potential than Steris PLC, analysts believe Boston Scientific is more attractive than Steris PLC.

Steris PLC has a beta of 0.873, which suggesting that the stock is 12.657% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 53.03% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are smaller than Boston Scientific quarterly revenues of $4.6B. Steris PLC's net income of $173.5M is lower than Boston Scientific's net income of $566M. Notably, Steris PLC's price-to-earnings ratio is 47.33x while Boston Scientific's PE ratio is 77.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.10x versus 8.59x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Edwards Lifesciences has a net margin of 12.66% compared to Steris PLC's net margin of 27.83%. Steris PLC's return on equity of 7.27% beat Edwards Lifesciences's return on equity of 50.81%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 12.2%. On the other hand Edwards Lifesciences has an analysts' consensus of $80.18 which suggests that it could grow by 14.7%. Given that Edwards Lifesciences has higher upside potential than Steris PLC, analysts believe Edwards Lifesciences is more attractive than Steris PLC.

Steris PLC has a beta of 0.873, which suggesting that the stock is 12.657% less volatile than S&P 500. In comparison Edwards Lifesciences has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.863%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. Edwards Lifesciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 53.03% of its earnings as a dividend. Edwards Lifesciences pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are smaller than Edwards Lifesciences quarterly revenues of $1.4B. Steris PLC's net income of $173.5M is lower than Edwards Lifesciences's net income of $385.6M. Notably, Steris PLC's price-to-earnings ratio is 47.33x while Edwards Lifesciences's PE ratio is 10.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.10x versus 7.32x for Edwards Lifesciences. Usually stocks with elevated PS ratios are considered overvalued.

Hologic has a net margin of 12.66% compared to Steris PLC's net margin of 19.67%. Steris PLC's return on equity of 7.27% beat Hologic's return on equity of 15.28%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 12.2%. On the other hand Hologic has an analysts' consensus of $77.53 which suggests that it could grow by 30.72%. Given that Hologic has higher upside potential than Steris PLC, analysts believe Hologic is more attractive than Steris PLC.

Steris PLC has a beta of 0.873, which suggesting that the stock is 12.657% less volatile than S&P 500. In comparison Hologic has a beta of 0.825, suggesting its less volatile than the S&P 500 by 17.493%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. Hologic offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Steris PLC pays 53.03% of its earnings as a dividend. Hologic pays out -- of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are larger than Hologic quarterly revenues of $1B. Steris PLC's net income of $173.5M is lower than Hologic's net income of $201M. Notably, Steris PLC's price-to-earnings ratio is 47.33x while Hologic's PE ratio is 18.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.10x versus 3.46x for Hologic. Usually stocks with elevated PS ratios are considered overvalued.

Zimmer Biomet Holdings has a net margin of 12.66% compared to Steris PLC's net margin of 11.84%. Steris PLC's return on equity of 7.27% beat Zimmer Biomet Holdings's return on equity of 7.21%.

Steris PLC has a consensus price target of $250.13, signalling upside risk potential of 12.2%. On the other hand Zimmer Biomet Holdings has an analysts' consensus of $122.27 which suggests that it could grow by 18.21%. Given that Zimmer Biomet Holdings has higher upside potential than Steris PLC, analysts believe Zimmer Biomet Holdings is more attractive than Steris PLC.

Steris PLC has a beta of 0.873, which suggesting that the stock is 12.657% less volatile than S&P 500. In comparison Zimmer Biomet Holdings has a beta of 0.843, suggesting its less volatile than the S&P 500 by 15.664%.

Steris PLC has a quarterly dividend of $0.57 per share corresponding to a yield of 1%. Zimmer Biomet Holdings offers a yield of 0.93% to investors and pays a quarterly dividend of $0.24 per share. Steris PLC pays 53.03% of its earnings as a dividend. Zimmer Biomet Holdings pays out 21.69% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Steris PLC quarterly revenues are $1.4B, which are smaller than Zimmer Biomet Holdings quarterly revenues of $2B. Steris PLC's net income of $173.5M is lower than Zimmer Biomet Holdings's net income of $239.5M. Notably, Steris PLC's price-to-earnings ratio is 47.33x while Zimmer Biomet Holdings's PE ratio is 23.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Steris PLC is 4.10x versus 2.75x for Zimmer Biomet Holdings. Usually stocks with elevated PS ratios are considered overvalued.